Pasar al contenido principal

TRAZADO DE LINAJE DE NUEVAS POBLACIONES PANCREATICAS DUCTALES CON CAPACIDAD PROGENITORA (LY6D AND LY6A) Y SU NICHO, COMO POSIBLE TERAPIA CELULAR EN DIABETES

PID2022-136973OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity

  • Martínez Bosch, Neus
  • Manero Rupérez, Noemí
  • Vázquez-Bellón, Núria
  • Nickell-Hernández, Bennett
  • Ventura-Blanch, Cristina
  • Lutfi, Nura
  • Lechuga, Carmen G.
  • Martínez, Carlos
  • Moreno, Mireia
  • Ampurdanés, Coral
  • Abad Cortel, Etna
  • Iglesias Coma, Mar
  • Muñoz-Escribano, María
  • Janic, Ana
  • Rovira, Meritxell
  • Guerra, Carmen
  • Rabinovich, Gabriel A.
  • Yélamos López, José
  • Navarro, Pilar
Pancreatic cancer represents one of the most lethal tumors, characterized by an immunosuppressive microenvironment and a lack of cytotoxic immune cell infiltrates, which confer resistance to immunotherapy. Here, we demonstrate that deletion of poly(ADP-ribose) polymerase 2 (PARP2) in a Myc-driven mouse model of pancreatic cancer delays tumor progression and increases survival. Mechanistically, PARP2 loss induces enrichment of pathways associated with genomic instability and replicative stress, leading to increased γH2AX, chromosomal instability, and micronuclei accumulation. In addition to these tumor-intrinsic effects, PARP2 deletion reshapes the tumor microenvironment, promoting infiltration of cytotoxic T and natural killer cells while reducing immunosuppressive cell populations, enhancing antitumor cytotoxicity. These findings are recapitulated in a KrasG12D-driven orthotopic pancreatic ductal adenocarcinoma model. Collectively, our data support selective PARP2 inhibition as a promising therapeutic strategy for pancreatic cancer by impairing genome integrity and boosting antitumor immune response, thereby opening potential avenues for combating this devastating disease., This work was supported by the following grants: Spanish Ministry of Science, Innovation and Universities (MICIU)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF “A way of making Europe”) grants PI20/00625 and PI23/00591 (P.N.); Spanish Ministry of Science, Innovation and Universities (MICIU)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF “A way of making Europe”) grant PI19/00514 (C.G.); Carmen Delgado/Miguel Pérez Mateo Grants-Asociación Cancer de Páncreas and Asociación Española de Pancreatología (P.N., C.G., and J.Y.); Spanish Ministry of Science, Innovation, and Universities (MICIU/AEI /10.13039/501100011033, co-funded by the European Union) grant PID2023-146049OB-I00 (J.Y.); Spanish Ministry of Science, Innovation, and Universities (MICIU) grant PID2021-127710OB-I00 (A.J.); Spanish Ministry of Science, Innovation, and Universities (MICIU) grant PID2022-136973OB-I00 (M.R.); Cancer Research Innovation in Science (CRIS) Cancer Foundation (Excellence Grant) (M.R.); Ramón y Cajal Research Fellowship grant RYC2018-025244-I (A.J.); Ministerio de Ciencia, Tecnología e Innovación (Redes Federales de Alto Impacto) (G.A.R.); and Sales and Baron Foundations (G.A.R.).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

ΔNP63 defines an exocrine-committed subset of murine pancreatic progenitor cells

  • Coolens, Katarina
  • Van der Vliet, Melissa
  • Van Campenhout, Jente
  • Del Pozo, Natalia
  • Torres-Cano, Alejo
  • Olsen, Catharina
  • Xu, Jianming
  • Romano, Rose-Anne
  • Lickert, Heiko
  • Rovira, Meritxell
  • Houbracken, Isabelle
  • Baldan, Jonathan
  • Real, Francisco X.
  • Spagnoli, Francesca M.
  • Rooman, Ilse
This work is supported by Fonds Wetenschappelijk Onderzoek (FWO, G0A7322N) and Wetenschappelijk Fonds Willy Gepts. Katarina Coolens is a recipient of a PhD Fellowship of the FWO (1157221N) and of the Award Cancer Research - Oncology Center Vrije Universiteit Brussel, funded by the bequests of Ms Esther Desmedt and Ms Irma Noë. Isabelle Houbracken was financially supported by the bequests of Ms Esther Desmedt and Ms Irma Noë. Jonathan Baldan is supported by a Foundation Against Cancer Fundamental mandate (2023-038). Meritxell Rovira is supported by Ministerio de Ciencia, Innovación y Universidades (MICIN) (PID2022-136973OB-I00). Work in the laboratory of Francisco X. Real is supported by grant PID2021-128125OB-I00 from Ministerio de Ciencia, Innovación y Universidades (Madrid, Spain). Catharina N.I. Olsen is supported by MCIU as a Centro de Excelencia Severo Ochoa (grant SEV-2015-0510).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity

  • Martínez Bosch, Neus
  • Manero Rupérez, Noemí
  • Vázquez-Bellón, Núria
  • Nickell-Hernández, Bennett
  • Ventura-Blanch, Cristina
  • Lutfi, Nura
  • Lechuga, Carmen G.
  • Martínez, Carlos
  • Moreno, Mireia
  • Ampurdanés, Coral
  • Abad Cortel, Etna
  • Iglesias Coma, Mar
  • Muñoz-Escribano, María
  • Janic, Ana
  • Rovira, Meritxell
  • Guerra, Carmen
  • Rabinovich, Gabriel A.
  • Yélamos López, José
  • Navarro, Pilar
Pancreatic cancer represents one of the most lethal tumors, characterized by an immunosuppressive microenvironment and a lack of cytotoxic immune cell infiltrates, which confer resistance to immunotherapy. Here, we demonstrate that deletion of poly(ADP-ribose) polymerase 2 (PARP2) in a Myc-driven mouse model of pancreatic cancer delays tumor progression and increases survival. Mechanistically, PARP2 loss induces enrichment of pathways associated with genomic instability and replicative stress, leading to increased γH2AX, chromosomal instability, and micronuclei accumulation. In addition to these tumor-intrinsic effects, PARP2 deletion reshapes the tumor microenvironment, promoting infiltration of cytotoxic T and natural killer cells while reducing immunosuppressive cell populations, enhancing antitumor cytotoxicity. These findings are recapitulated in a KrasG12D-driven orthotopic pancreatic ductal adenocarcinoma model. Collectively, our data support selective PARP2 inhibition as a promising therapeutic strategy for pancreatic cancer by impairing genome integrity and boosting antitumor immune response, thereby opening potential avenues for combating this devastating disease., This work was supported by the following grants: Spanish Ministry of Science, Innovation and Universities (MICIU)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF “A way of making Europe”) grants PI20/00625 and PI23/00591 (P.N.); Spanish Ministry of Science, Innovation and Universities (MICIU)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF “A way of making Europe”) grant PI19/00514 (C.G.); Carmen Delgado/Miguel Pérez Mateo Grants-Asociación Cancer de Páncreas and Asociación Española de Pancreatología (P.N., C.G., and J.Y.); Spanish Ministry of Science, Innovation, and Universities (MICIU/AEI /10.13039/501100011033, co-funded by the European Union) grant PID2023-146049OB-I00 (J.Y.); Spanish Ministry of Science, Innovation, and Universities (MICIU) grant PID2021-127710OB-I00 (A.J.); Spanish Ministry of Science, Innovation, and Universities (MICIU) grant PID2022-136973OB-I00 (M.R.); Cancer Research Innovation in Science (CRIS) Cancer Foundation (Excellence Grant) (M.R.); Ramón y Cajal Research Fellowship grant RYC2018-025244-I (A.J.); Ministerio de Ciencia, Tecnología e Innovación (Redes Federales de Alto Impacto) (G.A.R.); and Sales and Baron Foundations (G.A.R.).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

ΔNP63 defines an exocrine-committed subset of murine pancreatic progenitor cells

  • Coolens, Katarina
  • Van der Vliet, Melissa
  • Van Campenhout, Jente
  • Del Pozo, Natalia
  • Torres-Cano, Alejo
  • Olsen, Catharina
  • Xu, Jianming
  • Romano, Rose-Anne
  • Lickert, Heiko
  • Rovira, Meritxell
  • Houbracken, Isabelle
  • Baldan, Jonathan
  • Real, Francisco X.
  • Spagnoli, Francesca M.
  • Rooman, Ilse
This work is supported by Fonds Wetenschappelijk Onderzoek (FWO, G0A7322N) and Wetenschappelijk Fonds Willy Gepts. Katarina Coolens is a recipient of a PhD Fellowship of the FWO (1157221N) and of the Award Cancer Research - Oncology Center Vrije Universiteit Brussel, funded by the bequests of Ms Esther Desmedt and Ms Irma Noë. Isabelle Houbracken was financially supported by the bequests of Ms Esther Desmedt and Ms Irma Noë. Jonathan Baldan is supported by a Foundation Against Cancer Fundamental mandate (2023-038). Meritxell Rovira is supported by Ministerio de Ciencia, Innovación y Universidades (MICIN) (PID2022-136973OB-I00). Work in the laboratory of Francisco X. Real is supported by grant PID2021-128125OB-I00 from Ministerio de Ciencia, Innovación y Universidades (Madrid, Spain). Catharina N.I. Olsen is supported by MCIU as a Centro de Excelencia Severo Ochoa (grant SEV-2015-0510).